Market revenue in 2023 | USD 3,759.1 million |
Market revenue in 2030 | USD 6,020.5 million |
Growth rate | 7% (CAGR from 2023 to 2030) |
Largest segment | Api |
Fastest growing segment | API |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | API, Drug Product |
Key market players worldwide | Lonza Group Ltd, Thermo Fisher Scientific Inc, Labcorp Holdings Inc, Catalent Inc, Wuxi AppTec Co Ltd, Siegfried Holding AG, Nipro Corp, Piramal Pharma Solutions, Recipharm Venture Fund, CordenPharma, Cambrex, Bushu Pharmaceuticals, Seqens |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical cdmo market will help companies and investors design strategic landscapes.
Api was the largest segment with a revenue share of 80.89% in 2023. Horizon Databook has segmented the Mexico pharmaceutical cdmo market based on api, drug product covering the revenue growth of each sub-segment from 2018 to 2030.
According to the International Trade Administration, updated in November 2023, Mexico is the 15thlargest market for pharmaceuticals globally and the second largest in Latin America after Brazil. In addition, the country’s pharmaceutical market is divided into patented medicines.
With the remaining 14% by value. Therefore, the growing pharmaceutical market promotes the demand for generics & biologics in Mexico, fueling the demand for pharmaceutical CDMO. Mexico is attracting international pharma companies and CDMOs.
In addition, the country provides a favorable market environment to attract R&D investment and expansion, stimulating the demand for CDMO. Most pharmaceutical companies in the country are gradually expanding & modernizing their development and production criteria.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico pharmaceutical cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Mexico pharmaceutical cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account